ATE461217T1 - Glp-1-verbindungen - Google Patents
Glp-1-verbindungenInfo
- Publication number
- ATE461217T1 ATE461217T1 AT04803037T AT04803037T ATE461217T1 AT E461217 T1 ATE461217 T1 AT E461217T1 AT 04803037 T AT04803037 T AT 04803037T AT 04803037 T AT04803037 T AT 04803037T AT E461217 T1 ATE461217 T1 AT E461217T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- glp
- therapeutic use
- novel glp
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301885 | 2003-12-18 | ||
DKPA200401090 | 2004-07-09 | ||
PCT/DK2004/000886 WO2005058954A1 (en) | 2003-12-18 | 2004-12-17 | Novel glp-1 compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE461217T1 true ATE461217T1 (de) | 2010-04-15 |
Family
ID=34702152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04803037T ATE461217T1 (de) | 2003-12-18 | 2004-12-17 | Glp-1-verbindungen |
Country Status (12)
Country | Link |
---|---|
US (2) | US20070042956A1 (de) |
EP (1) | EP1704165B1 (de) |
JP (1) | JP2007537141A (de) |
KR (1) | KR20060135661A (de) |
AT (1) | ATE461217T1 (de) |
AU (1) | AU2004298424A1 (de) |
BR (1) | BRPI0417717A (de) |
CA (1) | CA2549582A1 (de) |
DE (1) | DE602004026113D1 (de) |
MX (1) | MXPA06006745A (de) |
RU (1) | RU2006120079A (de) |
WO (1) | WO2005058954A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA92451C2 (en) | 2003-03-19 | 2010-11-10 | Эли Лилли Энд Компани | Polyethelene glycol link glp-1 compounds |
CA2549582A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
KR20070108180A (ko) * | 2005-02-16 | 2007-11-08 | 노보 노르디스크 에이/에스 | 구조적으로 잘 정의된 분지형 중합체와 콘쥬게이트된인슐린분비제 유도체 |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
WO2006097538A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended glp-1 compounds |
WO2007047834A2 (en) * | 2005-10-18 | 2007-04-26 | Biocon Limited | Oral peptide conjugates for metabolic diseases |
EP1942941A1 (de) | 2005-10-26 | 2008-07-16 | Eli Lilly And Company | Selektive peptidische agonisten des vpac2-rezeptors |
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
ES2390286T3 (es) | 2005-12-16 | 2012-11-08 | Nektar Therapeutics | Conjugados poliméricos de GLP-1 |
EP2007804B1 (de) * | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1-verbindungen |
FR2904627B1 (fr) * | 2006-08-04 | 2008-11-07 | Pasteur Institut | Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation |
CN101125207B (zh) | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
CA2674354A1 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
US8895694B2 (en) | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
EP2190873B1 (de) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Verkürzte glp-1-derivate und ihre therapeutische verwendung |
US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
EP2200626A4 (de) * | 2007-09-07 | 2012-02-15 | Ipsen Pharma Sas | Analoga von exendin-4 und exendin-3 |
GB0717399D0 (en) * | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
CA2702289A1 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
EP2217701B9 (de) * | 2007-10-30 | 2015-02-18 | Indiana University Research and Technology Corporation | Glucagon-antagonisten |
CN101983066B (zh) * | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
EP2087911A1 (de) | 2008-02-06 | 2009-08-12 | Institut Pasteur | Konjugierte Moleküle mit einem Peptid aus dem mit einem Polyanion gekoppelten CD4-Rezeptor zur Behandlung von AIDS |
US20110147197A1 (en) * | 2008-06-11 | 2011-06-23 | Jian Xie | Methods for enhancing adsorption of molecules |
PE20100255A1 (es) | 2008-06-17 | 2010-04-25 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
KR20110039230A (ko) * | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
CN104945500B (zh) * | 2008-06-17 | 2019-07-09 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
TW201012829A (en) * | 2008-09-22 | 2010-04-01 | Ipsen Mfg Ireland Ltd | Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2 |
MX2011006524A (es) | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
US8513192B2 (en) | 2009-01-22 | 2013-08-20 | Novo Nordisk A/S | Stable growth hormone compounds resistant to proteolytic degradation |
AU2010260058B2 (en) | 2009-06-16 | 2015-09-24 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
CN105963710A (zh) | 2009-08-06 | 2016-09-28 | 诺沃—诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
EP2513140B1 (de) | 2009-12-16 | 2015-11-04 | Novo Nordisk A/S | Zweifach acylierte glp-1-derivate |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
CN106139158B (zh) | 2010-01-22 | 2024-06-21 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
CN102834108A (zh) | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
BR112012028707A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. |
RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
JP2013540102A (ja) | 2010-06-24 | 2013-10-31 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ |
SI3326620T1 (sl) | 2010-12-16 | 2020-07-31 | Novo Nordisk A/S | Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline |
BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
RU2602601C2 (ru) | 2011-04-12 | 2016-11-20 | Ново Нордиск А/С | Дважды ацилированные производные glp-1 |
ME02816B (me) | 2011-06-22 | 2018-01-20 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
AU2012273365A1 (en) | 2011-06-22 | 2014-01-16 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
JP6001158B2 (ja) | 2012-03-22 | 2016-10-05 | ノヴォ ノルディスク アー/エス | Glp−1ペプチドの組成物、及びその調製 |
PL2827845T3 (pl) | 2012-03-22 | 2019-06-28 | Novo Nordisk A/S | Kompozycje zawierające substancję dostarczającą i ich wytwarzanie |
WO2013167454A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
ES2629735T3 (es) * | 2012-05-08 | 2017-08-14 | Novo Nordisk A/S | Derivados de GLP-1 doblemente acilados |
EP2863895B1 (de) | 2012-06-20 | 2021-04-14 | Novo Nordisk A/S | Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler |
EP2864351B1 (de) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagonanaloga mit gip-rezeptoraktivität |
JP2016500682A (ja) | 2012-10-17 | 2016-01-14 | ノヴォ ノルディスク アー/エス | 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸 |
WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
JP6464145B2 (ja) | 2013-04-05 | 2019-02-06 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン化合物製剤 |
CN105934257B (zh) | 2013-12-06 | 2020-10-09 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
EP3206710B1 (de) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Inkretininsulinkonjugate |
ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
EP3359181A1 (de) | 2015-10-07 | 2018-08-15 | Cyprumed GmbH | Pharmazeutische formulierungen zur oralen verabreichung von peptidarzneimitteln |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
TWI804571B (zh) | 2018-02-02 | 2023-06-11 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物 |
US20210087250A1 (en) | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
EP3897570A1 (de) | 2018-12-19 | 2021-10-27 | KRKA, d.d., Novo mesto | Pharmazeutische zusammensetzung mit glp-1-analog |
WO2021123228A1 (en) | 2019-12-18 | 2021-06-24 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
JP2023513272A (ja) | 2020-02-07 | 2023-03-30 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
CN111253475B (zh) * | 2020-02-18 | 2021-03-09 | 江苏诺泰澳赛诺生物制药股份有限公司 | Glp-1激动多肽化合物及其盐与合成方法及用途 |
WO2021219710A1 (en) | 2020-04-29 | 2021-11-04 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
WO2022028572A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
US20240041983A1 (en) | 2020-09-07 | 2024-02-08 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862167A (en) | 1965-08-11 | 1975-01-21 | Mitsui Toatsu Chemicals | Certain 2-acylamine-4-methyl-5-halothiazoles |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
UA72181C2 (uk) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння |
AU2610699A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
AU764371B2 (en) | 1998-08-28 | 2003-08-14 | Eli Lilly And Company | Method for administering insulinotropic peptides |
MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
ATE282635T1 (de) * | 1998-12-07 | 2004-12-15 | Sod Conseils Rech Applic | Glp-1 analoge |
JP2002544127A (ja) * | 1999-04-30 | 2002-12-24 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 修飾されたエキセンジンおよびエキセンジン・アゴニスト |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
EP1076066A1 (de) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
AU2353701A (en) | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法 |
UA92451C2 (en) * | 2003-03-19 | 2010-11-10 | Эли Лилли Энд Компани | Polyethelene glycol link glp-1 compounds |
EP2264066A3 (de) | 2003-08-05 | 2011-07-27 | Novo Nordisk A/S | Neue Insulinderivate |
JP2008505048A (ja) * | 2003-09-19 | 2008-02-21 | ザ スクリップス リサーチ インスティテュート | 4E10Fabフラグメント複合体の広範囲中和性抗HIV抗体構造に結合するペプチド、それらの使用、それら由来の組成物 |
CA2549582A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
RU2407557C2 (ru) | 2005-07-27 | 2010-12-27 | Ново Нордиск А/С | Инъекционное устройство с механизмом ограничения дозы и предохранительным механизмом |
CN101912648B (zh) | 2008-01-23 | 2013-04-24 | 诺沃-诺迪斯克有限公司 | 用于注射所分配剂量的液体药物的设备 |
-
2004
- 2004-12-17 CA CA002549582A patent/CA2549582A1/en not_active Abandoned
- 2004-12-17 KR KR1020067011699A patent/KR20060135661A/ko not_active Application Discontinuation
- 2004-12-17 JP JP2006544220A patent/JP2007537141A/ja not_active Withdrawn
- 2004-12-17 RU RU2006120079/13A patent/RU2006120079A/ru unknown
- 2004-12-17 DE DE602004026113T patent/DE602004026113D1/de active Active
- 2004-12-17 MX MXPA06006745A patent/MXPA06006745A/es not_active Application Discontinuation
- 2004-12-17 AU AU2004298424A patent/AU2004298424A1/en not_active Abandoned
- 2004-12-17 WO PCT/DK2004/000886 patent/WO2005058954A1/en active Application Filing
- 2004-12-17 EP EP04803037A patent/EP1704165B1/de not_active Revoked
- 2004-12-17 AT AT04803037T patent/ATE461217T1/de not_active IP Right Cessation
- 2004-12-17 BR BRPI0417717-7A patent/BRPI0417717A/pt not_active IP Right Cessation
-
2006
- 2006-06-16 US US11/454,804 patent/US20070042956A1/en not_active Abandoned
-
2012
- 2012-05-16 US US13/473,154 patent/US9920106B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2004298424A1 (en) | 2005-06-30 |
DE602004026113D1 (de) | 2010-04-29 |
BRPI0417717A (pt) | 2007-04-03 |
US20120289453A1 (en) | 2012-11-15 |
JP2007537141A (ja) | 2007-12-20 |
KR20060135661A (ko) | 2006-12-29 |
US9920106B2 (en) | 2018-03-20 |
EP1704165A1 (de) | 2006-09-27 |
MXPA06006745A (es) | 2006-08-18 |
WO2005058954A1 (en) | 2005-06-30 |
US20070042956A1 (en) | 2007-02-22 |
RU2006120079A (ru) | 2008-01-27 |
EP1704165B1 (de) | 2010-03-17 |
CA2549582A1 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE461217T1 (de) | Glp-1-verbindungen | |
NO20052914D0 (no) | Terapeutiske forbindelser | |
NO20053974D0 (no) | Tienopyrimidinforbindelser og anvendelse derav. | |
NL1025404A1 (nl) | Pyrazolo-triazine verbindingen en gebruik daarvan. | |
SE0301653D0 (sv) | Novel compounds | |
DK1572229T3 (da) | Stabilt terapeutisk fibrinogen | |
SE0301650D0 (sv) | Novel compounds | |
NL1024677A1 (nl) | Therapeutische prolinederivaten. | |
DK1597171T3 (da) | Terapeutisk mikroskum | |
DE50303099D1 (de) | Patientenlagerungstisch | |
NO20050689L (no) | Terapeutisk anvendelse | |
DK1553950T3 (da) | Terapeutisk behandling | |
ATE399532T1 (de) | Medizinische seife | |
NO20053189D0 (no) | HVC-kombinasjonsterapi. | |
IS7441A (is) | Peptíðdeformýlasatálmar | |
NO20022747L (no) | Behandlingsstol | |
FI20021817A0 (fi) | Kanyyli | |
DE60232650D1 (de) | Peptiddeformylaseinhibitoren | |
SE0302686L (sv) | Platt barnstol | |
SE0203826D0 (sv) | Therapeutic agents | |
SE0200450D0 (sv) | Therapeutic agents | |
SE0201783D0 (sv) | Medical use | |
SE0202239D0 (sv) | Novel use | |
SE0200410D0 (sv) | Novel use | |
UA6623S (uk) | Шприц |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |